We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.68B
1-Year Est. Return 375.52%
This Fund
S&P 500
This Quarter Est. Return
+49.77%
1 Year Est. Return
+375.52%
3 Year Est. Return
+2,120.72%
5 Year Est. Return
+8,694.03%
10 Year Est. Return
–
AUM
$664M
AUM Growth
+$41.7M
Cap. Flow
-$3.02M
Cap. Flow %
-0.45%
Top 10 Hldgs %
60.97%
Holding
41
New
11
Increased
8
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$25.5M
2
IMVT icon
Immunovant
IMVT
+$14.5M
3
ACLX
Arcellx
ACLX
+$13.6M
4
ELVN icon
Enliven Therapeutics
ELVN
+$9.97M
5
FDMT icon
4D Molecular Therapeutics
FDMT
+$9.24M

Top Sells

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$43.3M
2
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$22.3M
3
TCDA
Tricida, Inc. Common Stock
TCDA
+$20.7M
4
VRDN icon
Viridian Therapeutics
VRDN
+$15.6M
5
AKRO
Akero Therapeutics
AKRO
+$8.84M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CABA icon
26
Cabaletta Bio
CABA
$493M
$9.35M 1.41%
+1,010,359
New +$3.68M
PCVX icon
27
Vaxcyte
PCVX
$8.86B
$8.32M 1.25%
+173,481
New +$6.81M
KPTI icon
28
Karyopharm Therapeutics
KPTI
$38.3M
$6.58M 0.99%
129,041
– –
THRD
29
DELISTED
Third Harmonic Bio
THRD
$4.27M 0.64%
993,294
-25,275
-2% -$423K
LRMR icon
30
Larimar Therapeutics
LRMR
$402M
$3.1M 0.47%
750,000
– –
ABOS icon
31
Acumen Pharmaceuticals
ABOS
$206M
$2.69M 0.41%
498,315
-601,685
-55% -$4.04M
IMUX icon
32
Immunic
IMUX
$166M
$2.52M 0.38%
180,000
+90,699
+102% +$2.47M
RZLT icon
33
Rezolute
RZLT
$391M
$2.5M 0.38%
1,210,000
– –
KALV
34
DELISTED
KalVista Pharmaceuticals
KALV
$2.11M 0.32%
312,553
– –
DBVT
35
DBV Technologies
DBVT
$845M
$142K 0.02%
+9,269
New +$136K
CYTK icon
36
Cytokinetics
CYTK
$10.3B
– –
-893,646
Closed -$43.3M
ESPR
37
DELISTED
Esperion Therapeutics
ESPR
– –
-467,468
Closed -$3.13M
TERN
38
DELISTED
Terns Pharmaceuticals
TERN
– –
-205,870
Closed -$1.21M
STSA
39
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
– –
-3,711,286
Closed -$22.3M
TCDA
40
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-1,975,403
Closed -$20.7M
BLSA
41
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
– –
-250,000
Closed -$2.5M
1
2

Similar funds

TNBTD
Trustmark National Bank Trust Department Jackson, Mississippi $1.68B AUM 19.26% 1-Year Est. Return
PWMAG
Pinnacle Wealth Management Advisory Group Red Bank, New Jersey $1.68B AUM 31.18% 1-Year Est. Return
SH
Spear Holdings Dubai, United Arab Emirates $1.68B AUM 4.3% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
HCA
Heck Capital Advisors Rhinelander, Wisconsin $1.67B AUM 26.33% 1-Year Est. Return

Commodore Capital's Q4 2022 Portfolio in Review

As of Q4 2022, Commodore Capital held 41 positions worth $664M, up 6.7% from $622M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Commodore Capital's Q4 2022 filing shows 11 new, 8 increased, 7 reduced and 6 closed positions. Its largest new stake was Nuvalent: 913,621 shares worth $27.2M. The largest sale was Cytokinetics, an estimated $43.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • Commodore Capital's largest Q4 2022 buy was Nuvalent: 913,621 shares worth $27.2M.
  • Commodore Capital added most to Enanta Pharmaceuticals in Q4 2022, an estimated $5.47M increase.
  • Commodore Capital's biggest Q4 2022 reduction was Viridian Therapeutics, cutting an estimated $15.6M.
  • Commodore Capital fully exited Cytokinetics in Q4 2022, selling an estimated $43.3M.
  • Commodore Capital's ten largest holdings make up 61% of its $664M portfolio in Q4 2022.
  • Commodore Capital opened 11 new positions and closed 6 in Q4 2022.
  • Commodore Capital's portfolio value rose 6.7% quarter-over-quarter to $664M.

Based on Commodore Capital's 13F filing for Q4 2022, filed 14 Feb 2023.